Broad-spectrum Anti-human Immunodeficiency Virus (HIV) Potential of a Peptide HIV Type 1 Entry Inhibitor

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2007 Jan 26

PMID 17251295

Citations 24

Authors

Simon Cocklin

Hosahudya Gopi

Bianca Querido

Manideepthi Nimmagadda

Syna Kuriakose

Claudia Cicala

Sandya Ajith

Sabine Baxter

James Arthos

Julio Martin-Garcia

Irwin M Chaiken

Affiliations

Soon will be listed here.

Abstract

The AIDS epidemic continues to spread at an alarming rate worldwide, especially in developing countries. One approach to solving this problem is the generation of anti-human immunodeficiency virus (HIV) compounds with inhibition spectra broad enough to include globally prevailing forms of the virus. We have examined the HIV type 1 (HIV-1) envelope specificity of a recently identified entry inhibitor candidate, HNG-105, using surface plasmon resonance spectroscopy and pseudovirus inhibition assays. The combined results suggest that the HNG-105 molecule may be effective across the HIV-1 subtypes, and they highlight its potential as a lead for developing therapeutic and microbicidal agents to help combat the spread of AIDS.

Citing Articles

Design, synthesis, and mechanistic study of 2-piperazineone-bearing peptidomimetics as novel HIV capsid modulators.

Zhang X, Sun L, Xu S, Huang T, Zhao F, Ding D RSC Med Chem. 2023; 14(7):1272-1295.

PMID: 37484571 PMC: 10357934. DOI: 10.1039/d3md00134b.

Peptide Triazole Inhibitors of HIV-1: Hijackers of Env Metastability.

Carter E, Ang C, Chaiken I Curr Protein Pept Sci. 2022; 24(1):59-77.

PMID: 35692162 PMC: 11660822. DOI: 10.2174/1389203723666220610120927.

Design of new bis-triazolyl structure for identification of inhibitory activity on COVID-19 main protease by molecular docking approach.

Singh G, Pawan , Mohit , Diksha , Suman , Priyanka J Mol Struct. 2021; 1250:131858.

PMID: 34744185 PMC: 8563301. DOI: 10.1016/j.molstruc.2021.131858.

Design, synthesis, and mechanism study of dimerized phenylalanine derivatives as novel HIV-1 capsid inhibitors.

Zhang X, Sun L, Meuser M, Zalloum W, Xu S, Huang T Eur J Med Chem. 2021; 226:113848.

PMID: 34592608 PMC: 9115767. DOI: 10.1016/j.ejmech.2021.113848.

Rapid Optimization of the Metabolic Stability of a Human Immunodeficiency Virus Type-1 Capsid Inhibitor Using a Multistep Computational Workflow.

Meuser M, Reddy P, Dick A, Maurancy J, Salvino J, Cocklin S J Med Chem. 2021; 64(7):3747-3766.

PMID: 33750123 PMC: 8043142. DOI: 10.1021/acs.jmedchem.0c01810.

References

Baldwin C, Sanders R, Berkhout B . Inhibiting HIV-1 entry with fusion inhibitors. Curr Med Chem. 2003; 10(17):1633-42. DOI: 10.2174/0929867033457124. View

Pierson T, Doms R . HIV-1 entry and its inhibition. Curr Top Microbiol Immunol. 2003; 281:1-27. DOI: 10.1007/978-3-642-19012-4_1. View

Biorn A, Cocklin S, Madani N, Si Z, Ivanovic T, Samanen J . Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions. Biochemistry. 2004; 43(7):1928-38. DOI: 10.1021/bi035088i. View

Tomkowicz B, Collman R . HIV-1 entry inhibitors: closing the front door. Expert Opin Ther Targets. 2004; 8(2):65-78. DOI: 10.1517/14728222.8.2.65. View

Fung H, Guo Y . Enfuvirtide: a fusion inhibitor for the treatment of HIV infection. Clin Ther. 2004; 26(3):352-78. DOI: 10.1016/s0149-2918(04)90032-x. View

Markovic I, Clouse K . Recent advances in understanding the molecular mechanisms of HIV-1 entry and fusion: revisiting current targets and considering new options for therapeutic intervention. Curr HIV Res. 2004; 2(3):223-34. DOI: 10.2174/1570162043351327. View

Dewhurst S, Embretson J, Anderson D, Mullins J, Fultz P . Sequence analysis and acute pathogenicity of molecularly cloned SIVSMM-PBj14. Nature. 1990; 345(6276):636-40. DOI: 10.1038/345636a0. View

OBRIEN W . HIV-1 entry and reverse transcription in macrophages. J Leukoc Biol. 1994; 56(3):273-7. DOI: 10.1002/jlb.56.3.273. View

Moore J, McCutchan F, Poon S, Mascola J, Liu J, Cao Y . Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol. 1994; 68(12):8350-64. PMC: 237304. DOI: 10.1128/JVI.68.12.8350-8364.1994. View

10.

Strizki J, Albright A, Sheng H, OConnor M, Perrin L . Infection of primary human microglia and monocyte-derived macrophages with human immunodeficiency virus type 1 isolates: evidence of differential tropism. J Virol. 1996; 70(11):7654-62. PMC: 190834. DOI: 10.1128/JVI.70.11.7654-7662.1996. View

11.

Moore J, Trkola A, Dragic T . Co-receptors for HIV-1 entry. Curr Opin Immunol. 1997; 9(4):551-62. DOI: 10.1016/s0952-7915(97)80110-0. View

12.

Kwong P, Wyatt R, Robinson J, Sweet R, Sodroski J, Hendrickson W . Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998; 393(6686):648-59. PMC: 5629912. DOI: 10.1038/31405. View

13.

Geretti A . HIV-1 subtypes: epidemiology and significance for HIV management. Curr Opin Infect Dis. 2005; 19(1):1-7. DOI: 10.1097/01.qco.0000200293.45532.68. View

14.

Gopi H, Tirupula K, Baxter S, Ajith S, Chaiken I . Click chemistry on azidoproline: high-affinity dual antagonist for HIV-1 envelope glycoprotein gp120. ChemMedChem. 2006; 1(1):54-7. DOI: 10.1002/cmdc.200500037. View

15.

Gray E, Meyers T, Gray G, Montefiori D, Morris L . Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med. 2006; 3(7):e255. PMC: 1502151. DOI: 10.1371/journal.pmed.0030255. View

16.

Ferrer M, Harrison S . Peptide ligands to human immunodeficiency virus type 1 gp120 identified from phage display libraries. J Virol. 1999; 73(7):5795-802. PMC: 112640. DOI: 10.1128/JVI.73.7.5795-5802.1999. View

17.

Binley J, Wrin T, Korber B, Zwick M, Wang M, Chappey C . Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol. 2004; 78(23):13232-52. PMC: 524984. DOI: 10.1128/JVI.78.23.13232-13252.2004. View

18.

Moore P, Cilliers T, Morris L . Predicted genotypic resistance to the novel entry inhibitor, BMS-378806, among HIV-1 isolates of subtypes A to G. AIDS. 2004; 18(17):2327-30. DOI: 10.1097/00002030-200411190-00015. View

19.

Kwong P . Human immunodeficiency virus: refolding the envelope. Nature. 2005; 433(7028):815-6. DOI: 10.1038/433815a. View

20.

Chen B, Vogan E, Gong H, Skehel J, Wiley D, Harrison S . Structure of an unliganded simian immunodeficiency virus gp120 core. Nature. 2005; 433(7028):834-41. DOI: 10.1038/nature03327. View